

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 31, 2025

Human TruStain FcX™ (Fc Receptor Blocking Solution)

RRID:AB_2818986

Type: Antibody

Proper Citation

(BioLegend Cat# 422302, RRID:AB_2818986)

Antibody Information

URL: http://antibodyregistry.org/AB_2818986

Proper Citation: (BioLegend Cat# 422302, RRID:AB_2818986)

Target Antigen: FC receptors

Host Organism: human

Clonality: unknown

Comments: Applications: FC, ICFC, ICC

Antibody Name: Human TruStain FcX™ (Fc Receptor Blocking Solution)

Description: This unknown targets FC receptors

Target Organism: human

Antibody ID: AB_2818986

Vendor: BioLegend

Catalog Number: 422302

Alternative Catalog Numbers: 422301

Record Creation Time: 20231110T032545+0000

Record Last Update: 20240725T030744+0000

Ratings and Alerts

No rating or validation information has been found for Human TruStain FcX™ (Fc Receptor Blocking Solution).

Warning: Discontinued: 2020
Applications: FC, ICFC, ICC

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 126 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Laforêts F, et al. (2024) Protocol for real-time monitoring of CD8+ T and myeloid cell behavior in human high-grade serous ovarian cancer slices. STAR protocols, 5(2), 103102.

Schmidt D, et al. (2024) Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF β Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment. Cancer research, 84(18), 2985.

Patra D, et al. (2024) Adipose tissue macrophage-derived microRNA-210-3p disrupts systemic insulin sensitivity by silencing GLUT4 in obesity. The Journal of biological chemistry, 300(6), 107328.

Kim Y, et al. (2024) Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell host & microbe, 32(8), 1380.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Yamada K, et al. (2024) Protocol for immunophenotyping out-of-hospital cardiac arrest patients. STAR protocols, 5(1), 102874.

Kastenschmidt JM, et al. (2024) A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment. Cell stem cell, 31(3), 410.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. Cell reports, 43(4), 114041.

Sarna NS, et al. (2024) Enhanced and sustained T cell activation in response to fluid shear stress. *iScience*, 27(6), 109999.

Ran X, et al. (2024) Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas. *Cancer immunology research*, 12(2), 232.

Pahari S, et al. (2024) Protocol to develop human alveolar macrophage-like cells from mononuclear cells or purified monocytes for use in respiratory biology research. *STAR protocols*, 5(2), 103061.

Gupta T, et al. (2024) Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis. *Cancer cell*, 42(5), 797.

Kotliar D, et al. (2024) Reproducible single cell annotation of programs underlying T-cell subsets, activation states, and functions. *bioRxiv : the preprint server for biology*.

Shao X, et al. (2024) Generation of a conditional cellular senescence model using proximal tubule cells and fibroblasts from human kidneys. *Cell death discovery*, 10(1), 364.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Wang Q, et al. (2024) The CARD8 inflammasome dictates HIV/SIV pathogenesis and disease progression. *Cell*, 187(5), 1223.

Walker GT, et al. (2024) CCL28 modulates neutrophil responses during infection with mucosal pathogens. *eLife*, 13.

Hashimoto N, et al. (2024) Bidirectional signals generated by Siglec-7 and its crucial ligand tri-sialylated T to escape of cancer cells from immune surveillance. *iScience*, 27(11), 111139.

Tasis A, et al. (2024) Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine. *Cancer research communications*, 4(12), 3067.

Orsenigo F, et al. (2024) Unifying considerations and evidence of macrophage activation mosaicism through human CSF1R and M1/M2 genes. *Cell reports*, 43(6), 114352.